The Peptide Reference
The Peptide Reference
References
Reference/Growth hormone secretagogue

Ipamorelin

Growth Hormone Secretagogue · Selective GHRP

Human clinical
research use only

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

Optimal GH stimulation with superior bioavailabilityBody composition improvements (lean mass, fat loss)Enhanced recovery and anti-aging effectsMinimal side effects compared to other GHRPs
01

Overview

Selective GHRP that stimulates natural GH production from the pituitary with minimal cortisol and prolactin disruption. Known for its excellent safety profile and ability to produce consistent GH pulses without significant side effects common to other growth hormone releasing peptides.

Binds selectively to ghrelin receptors in pituitary gland, stimulating natural GH release with direct systemic delivery via injection, consistent GH pulse stimulation, no significant cortisol or prolactin elevation, and minimal hunger response.

Evidence profilederived from 5 references
A
Human clinical
Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.
02

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Growth Hormone3
Natural GH Stimulation

Consistent GH elevation 30-60 minutes post-injection, maintaining natural pulsatile patterns.

Large
IGF-1 Enhancement

Increases insulin-like growth factor-1 through natural GH pathways.

Moderate
Anti-Aging Benefits

Supports cellular regeneration, collagen synthesis, and tissue repair.

Moderate
Body Composition2
Lean Mass Development

Promotes muscle growth and maintenance through GH-mediated pathways.

Moderate
Fat Loss Support

Enhances lipolysis and metabolic rate through natural GH elevation.

Moderate
Recovery2
Sleep Quality

Improved sleep latency and increased slow-wave sleep duration.

Moderate
Exercise Recovery

Enhanced recovery markers and reduced soreness after training.

Small
i

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only
Class
Growth hormone secretagogue
Chain length
5 residues
Molecular weight
711.85 Da
Half-life
~2 h
Typical dose
200-300 mcg per injection
Frequency
1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
Cycle length
3-6 months
Storage
Lyophilized: Room temperature. Reconstituted: 2-8°C, use within 28 days
03

Molecular data

Type
Growth hormone secretagogue
Molecular weight
711.85 Da
Chain length
5 residues
Half-life
120 min
04

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

ContextRouteAmountFrequency
General Health & LongevitySubQ200mcg1x daily before bed
Body CompositionSubQ250-300mcg2x daily (morning, pre-workout)
Athletic PerformanceSubQ200-250mcg2-3x daily
Sleep & RecoverySubQ200mcg1x daily 30min before bed
Anti-Aging ProtocolSubQ200-250mcg1-2x daily
05

Interactions

CJC-1295

Extends GH release for optimal hormone cycles. Popular combination.

synergistic
BPC-157

Enhances GH receptor upregulation and effectiveness.

synergistic
TB-500

Complementary for recovery and tissue repair.

compatible
Sermorelin

Both stimulate GH; choose one to avoid receptor oversaturation.

monitor
GHRP-2

Redundant GH pathways may cause receptor desensitization.

avoid
GHRP-6

Similar mechanism with higher hunger effects; redundant.

avoid
06

Quality checklist

  • White, fine crystalline powder with no clumping
  • Clear solution after BAC water reconstitution
  • Mild hunger response 20-30 minutes post-injection
  • Slight drowsiness at bedtime doses
  • !Minimal or no physiological response after 2 weeks (check source)
  • ×Yellow or discolored powder (suggests degradation)
  • ×Cloudy solution after reconstitution
  • ×No response after extended use
07

What to expect

Week 1-2Improved sleep quality and morning energy
Week 2-4Enhanced exercise recovery and reduced soreness
Week 4-8Body composition improvements with increased lean mass
Week 8-12Continued muscle tone, skin quality, and energy improvements
08

Safety

Commonly reported3
  • Mild hunger increase 20-30 minutes post-injection
  • Slight drowsiness when taken before bed
  • Water retention (mild)
Stop and seek advice3
  • Signs of receptor desensitization (reduced response after 3-4 months)
  • Unusual joint pain or swelling
  • Persistent numbness or tingling
Contraindications3
  • Pregnancy or breastfeeding
  • Active cancer or history of cancer
  • Severe kidney or liver disease
09

FAQ

Why do users prefer ipamorelin over other GHRPs?

Ipamorelin is the most selective GHRP—it stimulates GH release without the appetite stimulation of GHRP-6, the prolactin elevation of GHRP-2, or the cortisol/ACTH effects of hexarelin. This selectivity makes it ideal for those wanting clean GH elevation with minimal side effects.

Is ipamorelin good for bedtime dosing?

Yes, excellent. A 200mcg dose 30 minutes before bed improves sleep quality and supports the natural nocturnal GH pulse. Many users report deeper, more restorative sleep with minimal side effects compared to morning dosing.

Can I stack ipamorelin with CJC-1295?

Yes, this is a popular and synergistic combination. CJC-1295 provides baseline GH elevation while ipamorelin adds pulsatile spikes. Together they extend GH release duration and amplitude beyond either peptide alone.

How long before ipamorelin stops working?

Ipamorelin typically maintains efficacy for 3-4 months before receptor desensitization develops. Many users take 4-week breaks every 12 weeks to reset receptor sensitivity and maintain responsiveness over time.

10

References

  1. 1
    Ipamorelin, the first selective growth hormone secretagogue
    Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998

    Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.

  2. 2
    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
    Zdravkovic, M., et al. · British Journal of Clinical Pharmacology · 1999

    Dose-escalation study in 40 healthy males established terminal half-life of 2 hours, clearance of 0.078 L/h/kg. Ipamorelin induced single-episode GH release peaking at 0.67 hours with dose-proportional pharmacokinetics.

  3. 3
    Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
    Johansen, P.B., et al. · Growth Hormone & IGF Research · 1999

    Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 mcm/day and produced pronounced dose-dependent body weight gain in adult female rats over 15 days.

  4. 4
    The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
    Svensson, J., et al. · Calcified Tissue International · 2001

    In 8-month-old female rats treated for 3 months, ipamorelin combined with glucocorticoid increased maximum tetanic tension and periosteal bone formation rate 4-fold compared to glucocorticoid alone.

  5. 5
    Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
    Greenwood-Van Meerveld, B., et al. · International Journal of Colorectal Disease · 2014

    Multicenter, double-blind, placebo-controlled trial in 117 bowel resection patients. Ipamorelin 0.03 mg/kg IV twice daily for up to 7 days was well tolerated but did not significantly improve postoperative ileus outcomes versus placebo.

For research use only. Nothing on this page is medical advice, and no number here is a recommendation to dose.